Inactive Instrument

Repertoire Genesis Inc.

Equities

9217

JP3981300001

Biotechnology & Medical Research

Eurofins Scientific SE acquires an unknown majority stake in Repertoire Genesis Inc.

May 30, 2022

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc. on May 31, 2022.

Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of an unknown majority stake in Repertoire Genesis Inc. on May 31, 2022.

Latest news about Repertoire Genesis Inc.

Eurofins Scientific SE acquires an unknown majority stake in Repertoire Genesis Inc.	22-05-30	CI
Repertoire Genesis Inc. has withdrawn its IPO in the amount of ¥929.475 million.	22-03-09	CI
Repertoire Genesis Inc. has filed an IPO.	22-02-10	CI

Chart Repertoire Genesis Inc.

Duration

Period

More charts

Company Profile

Repertoire Genesis Inc is a Japan-based company mainly engaged in the business of supporting medical development (basic research, prevention, diagnosis, and treatment) that applies the immune system, mainly in the fields of cancer, autoimmune diseases, and infectious diseases. The Company defines two sales categories, research and development support and clinical development support, based on the differences in the way development support services are provided. Research and development support is a category that supports customers' basic research and development, and is a business area that provides relatively small-scale research support services mainly to academia, such as universities and public research institutions, mainly through sales agents. Clinical development support is a business area that supports customers' applied clinical development and promotes relatively large-scale and long-term development projects using clinical samples, mainly for pharmaceutical companies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+21.85%	46.44B
LONZA GROUP AG	+37.63%	39.1B
IQVIA HOLDINGS INC.	-8.05%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.24B
CELLTRION, INC.	-13.75%	25.8B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.9B
MEDPACE HOLDINGS, INC.	+38.43%	13.12B
BIO-TECHNE CORPORATION	-6.92%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.68B

Other Biotechnology & Medical Research